Home
/
PHIBRO ANIMAL HEALTH CORP
/
Financials
/
Quarterly
PHIBRO ANIMAL HEALTH CORP — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PHIBRO ANIMAL HEALTH CORP filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Mar 31, 2022
$239.62M
May 4, 2022
Q2
2022
Dec 31, 2021
$232.71M
Feb 9, 2022
Q1
2022
Sep 30, 2021
$214.67M
Nov 2, 2021
Q3
2022
Mar 31, 2021
$211.73M
May 4, 2022
Q2
2022
Dec 31, 2020
$206.15M
Feb 9, 2022
Q1
2022
Sep 30, 2020
$195.19M
Nov 2, 2021
Q3
2021
Mar 31, 2020
$210.74M
May 6, 2021
Q2
2021
Dec 31, 2019
$214.01M
Feb 3, 2021
Q1
2021
Sep 30, 2019
$189.72M
Nov 4, 2020
Q3
2020
Mar 31, 2019
$205.74M
May 7, 2020
Q2
2020
Dec 31, 2018
$218.22M
Feb 3, 2020
Q1
2020
Sep 30, 2018
$200.15M
Nov 4, 2019
Q3
2019
Mar 31, 2018
$208.91M
May 6, 2019
Q2
2019
Dec 31, 2017
$205.88M
Feb 6, 2019
Q1
2019
Sep 30, 2017
$193.41M
Nov 6, 2018
Q3
2018
Mar 31, 2017
$189.86M
May 7, 2018
Q2
2018
Dec 31, 2016
$191.60M
Feb 5, 2018
Q1
2018
Sep 30, 2016
$187.99M
Nov 6, 2017
Q3
2017
Mar 31, 2016
$183.46M
May 8, 2017
Q2
2017
Dec 31, 2015
$191.77M
Feb 6, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
$373.91M
Feb 4, 2026
Q1
2026
Sep 30, 2025
$363.89M
Nov 5, 2025
Q3
2025
Mar 31, 2025
$347.83M
May 7, 2025
Q2
2026
Dec 31, 2024
$309.26M
Feb 4, 2026
Q1
2026
Sep 30, 2024
$260.43M
Nov 5, 2025
Q3
2025
Mar 31, 2024
$263.22M
May 7, 2025
Q2
2025
Dec 31, 2023
$249.94M
Feb 5, 2025
Q1
2025
Sep 30, 2023
$231.35M
Nov 6, 2024
Q3
2024
Mar 31, 2023
$245.67M
May 8, 2024
Q2
2024
Dec 31, 2022
$244.65M
Feb 7, 2024
Q1
2024
Sep 30, 2022
$232.52M
Nov 8, 2023
Q3
2023
Mar 31, 2022
$239.62M
May 3, 2023
Q2
2023
Dec 31, 2021
$232.71M
Feb 8, 2023
Q1
2023
Sep 30, 2021
$214.67M
Nov 9, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
$27.46M
Feb 4, 2026
Q1
2026
Sep 30, 2025
$26.53M
Nov 5, 2025
Q3
2025
Mar 31, 2025
$20.88M
May 7, 2025
Q2
2026
Dec 31, 2024
$3.19M
Feb 4, 2026
Q1
2026
Sep 30, 2024
$6.98M
Nov 5, 2025
Q3
2025
Mar 31, 2024
$8.41M
May 7, 2025
Q2
2025
Dec 31, 2023
$1.27M
Feb 5, 2025
Q1
2025
Sep 30, 2023
($8.02M)
Nov 6, 2024
Q3
2024
Mar 31, 2023
$10.04M
May 8, 2024
Q2
2024
Dec 31, 2022
$7.21M
Feb 7, 2024
Q1
2024
Sep 30, 2022
$3.86M
Nov 8, 2023
Q3
2023
Mar 31, 2022
$17.69M
May 3, 2023
Q2
2023
Dec 31, 2021
$17.47M
Feb 8, 2023
Q1
2023
Sep 30, 2021
$6.53M
Nov 9, 2022
Q3
2022
Mar 31, 2021
$12.16M
May 4, 2022
Q2
2022
Dec 31, 2020
$12.80M
Feb 9, 2022
Q1
2022
Sep 30, 2020
$12.30M
Nov 2, 2021
Q3
2021
Mar 31, 2020
$13.50M
May 6, 2021
Q2
2021
Dec 31, 2019
$11.89M
Feb 3, 2021
Q1
2021
Sep 30, 2019
$2.52M
Nov 4, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Dec 31, 2025
$50.33M
Feb 4, 2026
Q1
2026
Sep 30, 2025
$51.26M
Nov 5, 2025
Q3
2025
Mar 31, 2025
$33.52M
May 7, 2025
Q2
2026
Dec 31, 2024
$25.53M
Feb 4, 2026
Q1
2026
Sep 30, 2024
$17.70M
Nov 5, 2025
Q3
2025
Mar 31, 2024
$19.92M
May 7, 2025
Q2
2025
Dec 31, 2023
$15.70M
Feb 5, 2025
Q1
2025
Sep 30, 2023
($726.0K)
Nov 6, 2024
Q3
2024
Mar 31, 2023
$18.55M
May 8, 2024
Q2
2024
Dec 31, 2022
$15.84M
Feb 7, 2024
Q1
2024
Sep 30, 2022
$13.68M
Nov 8, 2023
Q3
2023
Mar 31, 2022
$19.19M
May 3, 2023
Q2
2023
Dec 31, 2021
$22.29M
Feb 8, 2023
Q1
2023
Sep 30, 2021
$14.61M
Nov 9, 2022
Q3
2022
Mar 31, 2021
$20.13M
May 4, 2022
Q2
2022
Dec 31, 2020
$19.89M
Feb 9, 2022
Q1
2022
Sep 30, 2020
$15.69M
Nov 2, 2021
Q3
2021
Mar 31, 2020
$21.32M
May 6, 2021
Q2
2021
Dec 31, 2019
$19.61M
Feb 3, 2021
Q1
2021
Sep 30, 2019
$10.15M
Nov 4, 2020